ArticleEuropean heart journal2021
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study.
Article in European heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05844566 (Implementation of a Decision Support System and Its Effect on Early Optimisation of Lipid-Lowering Therapies in Patients With Acute Coronary Syndrome), which is not on this map. Cited by 86 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Implementation of a Decision Support System and Its Effect on Early Optimisation of Lipid-Lowering Therapies in Patients With Acute Coronary Syndrome: a Cluster Randomised Controlled Trial
Who cites it
86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Guideline
- Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Latin-American guidelines of recommendations at discharge from an acute coronary syndrome.Archivos de cardiologia de Mexico · 2024Guideline
- Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials.Cardiovascular diabetology · 2023Pooled it
- Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.Journal of the American Heart Association · 2026Trial
- Changes in statin therapy following discharge in those with cardiovascular disease in Ireland.Irish journal of medical science · 2026Article
- The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management.Life (Basel, Switzerland) · 2026Review
- Association of Relative LDL-Cholesterol Reduction With Cardiovascular Outcomes After Percutaneous Coronary Intervention.Journal of atherosclerosis and thrombosis · 2026Article
- Molecular mechanisms of iron metabolism and ferroptosis in cardiovascular diseases and intervention strategies targeting natural products (Review).Molecular medicine reports · 2026Review
- Lipid-lowering therapy omission at discharge and one-year outcomes after percutaneous coronary intervention: a real-world analysis of overall and elderly patients.International journal of cardiology. Heart & vasculature · 2026Article
- [Austrian lipid consensus : Interdisciplinary evidence-based recommendations on prevention and treatment of lipid-associated diseases from 15 medical specialist societies].Wiener klinische Wochenschrift · 2026Article
- Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.American journal of preventive cardiology · 2026Article
- Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trial.European heart journal. Digital health · 2026Article
- Prescription of lipid-lowering drugs and their association with hospitalization for ST-elevation myocardial infarction (STEMI) in Germany in 2010-2022.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Identification of key biomarkers for myocardial infarction by multi-omics analysis and machine learning.Frontiers in immunology · 2026Article
- Association of cumulative remnant cholesterol exposure with adverse outcomes after PCI in acute ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy.European heart journal. Quality of care & clinical outcomes · 2025Article
- Prognostic significance and influencing factors of lipomatous metaplasia in patients after myocardial infarction.Insights into imaging · 2025Article
- Adherence trajectories of oral lipid-lowering therapy in patients with myocardial infarction and its estimated impact on low-density lipoprotein levels.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Simultaneous carotid ultrasound and transcranial Doppler to detect cholesterol crystal emboli from unstable carotid plaque to the brain.American heart journal plus : cardiology research and practice · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsClinical trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular (CV) events. This has, however, not yet been shown in a real-world setting. We aimed to investigate the association between LDL-C changes and statin intensity with prognosis after a myocardial infarction (MI). METHODS AND
resultsPatients admitted with MI were followed for mortality and major CV events. Changes in LDL-C between the MI and a 6- to 10-week follow-up visit were analysed. The associations between quartiles of LDL-C change and statin intensity with outcomes were assessed using adjusted Cox regression analyses. A total of 40 607 patients were followed for a median of 3.78 years. The median change in LDL-C was a 1.20 mmol/L reduction. Patients with larger LDL-C reduction (1.85 mmol/L, 75th percentile) compared with a smaller reduction (0.36 mmol/L, 25th percentile) had lower hazard ratios (HR) for all outcomes (95% confidence interval): composite of CV mortality, MI, and ischaemic stroke 0.77 (0.70-0.84); all-cause mortality 0.71 (0.63-0.80); CV mortality 0.68 (0.57-0.81); MI 0.81 (0.73-0.91); ischaemic stroke 0.76 (0.62-0.93); heart failure hospitalization 0.73 (0.63-0.85), and coronary artery revascularization 0.86 (0.79-0.94). Patients with ≥50% LDL-C reduction using high-intensity statins at discharge had a lower incidence of all outcomes compared with those using a lower intensity statin.
conclusionsLarger early LDL-C reduction and more intensive statin therapy after MI were associated with a reduced hazard of all CV outcomes and all-cause mortality. This supports clinical trial data suggesting that earlier lowering of LDL-C after an MI confers the greatest benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.